A lot of VEGFR2 neutralizing agents have been developed for cancer treatment, such as the human antibody bevacizumab (Avastin) [33], and the kinase inhibitors sunitinib, sorafenib, axitinib and vandetanib. Here, KDR is linked to cancer.